Upgrade to SI Premium - Free Trial

TD Cowen Reiterates Buy Rating on Guardant Health (GH) Following G360 Liquid FDA Approval

May 21, 2026 9:13 AM
TD Cowen analyst Dan Brennan reiterated a Buy rating and $127.00 price target on Guardant Health (NASDAQ: GH).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments